Stay updated on Amivantamab in Esophagogastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Amivantamab in Esophagogastric Cancer Clinical Trial page.

Latest updates to the Amivantamab in Esophagogastric Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe ClinicalTrials.gov page now displays the full record for a Phase II study of amivantamab in people with EGFR- or MET-amplified esophagogastric cancer, including study design, eligibility, treatment, and outcome details. It also provides study locations and information about sharing participant data.SummaryDifference44%

- Check18 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0. The study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide NIH banner announces a website transition and links to updates, stating that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check32 days agoChange DetectedThe page remains a 403 Forbidden error, and the displayed site revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1. The page continues to show a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check60 days agoChange DetectedThe study page shows a 403 Forbidden error, replacing the expected content with an access-denied notice and preventing viewing the record.SummaryDifference17%

Stay in the know with updates to Amivantamab in Esophagogastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab in Esophagogastric Cancer Clinical Trial page.